High response rates for bictegravir or dilutegraver with FTC/TAF for initial HIV therapy | CROI

Virologic success at week 24 was 97% for the bictegravir arm and 94% for the dilutegravir arm; at week 48 it was 97% and 91%, respectively.
Virologic success at week 24 was 97% for the bictegravir arm and 94% for the dilutegravir arm; at week 48 it was 97% and 91%, respectively.